DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Congestive Heart Failure market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congestive Heart Failure Market Forecast
Some of the key facts of the Congestive Heart Failure Market Report:
The Congestive Heart Failure market size was valued ~USD 6,900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In May 2025, BioCardia announced the enrollment of the first participant in its randomized, double-blind, placebo-controlled Phase III CardiAMP Heart Failure II trial, evaluating its autologous cell therapy for ischemic heart failure (HF). The first procedure was conducted at BayCare Morton Plant Hospital in Clearwater, Florida. The multicenter trial aims to enroll 250 patients and assess CardiAMP therapy as a one-time treatment for individuals with ischemic HF and reduced ejection fraction (HFrEF), who are already receiving guideline-directed medical therapy and exhibit elevated levels of N-terminal pro B-type natriuretic peptide (NTproBNP).
In May 2025, Medera Inc., a clinical-stage biopharmaceutical company developing next-generation therapies for cardiovascular diseases, announced that findings from its First-In-Human Phase 1/2a MUSIC-HFpEF trial will be presented at the upcoming Heart Failure 2025 Congress. The trial is evaluating SRD-002, an adeno-associated virus-based gene therapy candidate, for the treatment of heart failure with preserved ejection fraction (HFpEF).
In December 2024, Cytokinetics, Incorporated (Nasdaq: CYTK) announced that enrollment is now open for COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a confirmatory Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with symptomatic heart failure (HF) and severely reduced ejection fraction. Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator being developed as a potential treatment for heart failure with severely reduced ejection fraction. The COMET-HF trial is being conducted in collaboration with the Duke Clinical Research Institute (DCRI), a leading academic research organization.
According to estimates, the total number of diagnosed prevalent cases of CHF in the 7MM was around 21 million in 2023, with a higher prevalence in males than females.
The analysis of CHF across the 7MM reveals a clear trend, showing that patients with HFpEF make up a larger proportion (around 50%), as the heart is less severely affected and continues functioning with medication or symptomatic treatment. In contrast, patients with HFrEF experience more significant damage to the heart. As people age, the heart’s pumping ability declines.
In 2023, Class II of the New York Heart Association (NYHA) heart failure categories represented approximately 45% of the total diagnosed heart failure cases across the 7MM.
The majority of heart failure cases are found in individuals aged 60 years and older. In 2023, around 6.8 million heart failure cases in the US were attributed to this age group.
The growing focus of major players like AstraZeneca (FORXIGA), Novartis (ENTRESTO), Eli Lilly, and Boehringer Ingelheim (JARDIANCE) on label expansion and obtaining approval for treatments irrespective of patients’ left ventricular ejection fraction status is expected to drive the growth of the CHF drugs market, enabling them to reach a broader population.
Key Congestive Heart Failure Companies: Novartis, Boehringer Ingelheim, Elli Lilly, Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, Applied Therapeutics, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Merck Sharp & Dohme LLC, Corthera, Inc., AstraZeneca, GlaxoSmithKline, Otsuka Pharma, Scios, Inc., Janssen Pharma, Pharmacosmos A/S, Pfizer, GE Healthcare, and others
Key Congestive Heart Failure Therapies: ENTRESTO, JARDIANCE, MOUNJARO (tirzepatide), OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), KW-3902IV, Relaxin, Dapagliflozin, GSK716155, tolvaptan, Nesiritide, Iron oligosaccharide, Rosuvastatin, atorvastatin, 123I-mIBG, and others
The Congestive Heart Failure epidemiology based on gender heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age compared to men
The Congestive Heart Failure market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congestive Heart Failure pipeline products will significantly revolutionize the Congestive Heart Failure market dynamics.
Congestive Heart Failure Overview
Congestive heart failure (CHF), often simply referred to as heart failure, is a chronic medical condition in which the heart’s ability to pump blood efficiently is compromised. This results in inadequate blood flow to meet the body’s oxygen and nutrient demands, leading to a variety of symptoms and potential complication
Get a Free sample for the Congestive Heart Failure Market Report
https://www.delveinsight.com/report-store/congestive-heart-failure-market
Congestive Heart Failure Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Congestive Heart Failure Epidemiology Segmentation:
The Congestive Heart Failure market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Congestive Heart Failure
Prevalent Cases of Congestive Heart Failure by severity
Gender-specific Prevalence of Congestive Heart Failure
Diagnosed Cases of Episodic and Chronic Congestive Heart Failure
Download the report to understand which factors are driving Congestive Heart Failure epidemiology trends @ Congestive Heart Failure Epidemiology Forecast
Congestive Heart Failure Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congestive Heart Failure market or expected to get launched during the study period. The analysis covers Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Congestive Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Congestive Heart Failure Therapies and Key Companies
ENTRESTO: Novartis
JARDIANCE: Boehringer Ingelheim and Eli Lilly
MOUNJARO (tirzepatide): Eli Lilly and Company
OPC-61815: Otsuka pharmaceuticals
Omecamtivmecarbil: Cytokinetics
AZD4831: AstraZeneca
AT-001: Applied Therapeutics
Rexlemestrocel-L (Revascor): Mesoblast
Finerenone (Kerendia): Bayer
Finerenone (Kerendia): Novo Nordisk
Sotagliflozin: Lexicon Pharmaceuticals
Furoscix(furosemide injection): scPharmaceuticals
KW-3902IV: Merck Sharp & Dohme LLC
Relaxin: Corthera, Inc.
Dapagliflozin: AstraZeneca
GSK716155: GlaxoSmithKline
tolvaptan: Otsuka Pharma
nesiritide: Scios, Inc.
Nesiritide: Janssen Pharma
Iron oligosaccharide: Pharmacosmos A/S
Rosuvastatin: AstraZeneca
atorvastatin: Pfizer
123I-mIBG: GE Healthcare
Discover more about therapies set to grab major Congestive Heart Failure market share @ Congestive Heart Failure Treatment Market
Congestive Heart Failure Market Drivers
Robust emerging Congestive Heart Failure pipeline
Recent approval of therapies and promising emerging therapies
Evidence-based therapies
Aging of the population
Rising prevalence of the disease
Congestive Heart Failure Market Barriers
Availability of generic and off-label therapies in the market setting
Lack of confidence in diagnosis and management
Treatment failure to stimulate and follow society’s goals and requirements
Scope of the Congestive Heart Failure Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Congestive Heart Failure Therapeutic Assessment: Congestive Heart Failure current marketed and Congestive Heart Failure emerging therapies
Congestive Heart Failure Market Dynamics: Congestive Heart Failure market drivers and Congestive Heart Failure market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Congestive Heart Failure Unmet Needs, KOL’s views, Analyst’s views, Congestive Heart Failure Market Access and Reimbursement
To know more about Congestive Heart Failure companies working in the treatment market, visit @ Congestive Heart Failure Clinical Trials and Therapeutic Assessment
Table of Contents
1. Congestive Heart Failure Market Report Introduction
2. Executive Summary for Congestive Heart Failure
3. SWOT analysis of Congestive Heart Failure
4. Congestive Heart Failure Patient Share (%) Overview at a Glance
5. Congestive Heart Failure Market Overview at a Glance
6. Congestive Heart Failure Disease Background and Overview
7. Congestive Heart Failure Epidemiology and Patient Population
8. Country-Specific Patient Population of Congestive Heart Failure
9. Congestive Heart Failure Current Treatment and Medical Practices
10. Congestive Heart Failure Unmet Needs
11. Congestive Heart Failure Emerging Therapies
12. Congestive Heart Failure Market Outlook
13. Country-Wise Congestive Heart Failure Market Analysis (2020–2034)
14. Congestive Heart Failure Market Access and Reimbursement of Therapies
15. Congestive Heart Failure Market Drivers
16. Congestive Heart Failure Market Barriers
17. Congestive Heart Failure Appendix
18. Congestive Heart Failure Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
